Sonnet BioTherapeutics Holdings, Inc.(SONN)Earnings, Financials & Key Ratios
SONN•NASDAQ
$1.26
Price updated Apr 24, 2026
AboutSonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.Show more
- Revenue$1M+5268.8%
- EBITDA-$16M-34.7%
- Net Income-$16M-116.6%
- EPS (Diluted)-3.95+65.2%
- EBITDA Margin-1584.41%+97.5%
- Operating Margin-1584.41%+97.5%
- Net Margin-1611.27%+96.0%
- ROE-312.81%
SONN Price & Volume
Sonnet BioTherapeutics Holdings, Inc. (SONN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Deficits Threaten Clinical Development Runway
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Sonnet BioTherapeutics faces a precarious financial outlook characterized by a lack of recurring revenue and a reliance on dilutive equity financing to sustain its $2.4M quarterly R&D expenditure. The company's inability to achieve operational scale, evidenced by persistent quarterly operating losses often exceeding $3.5M, suggests significant execution risk for its FHAB platform. Investors should monitor the firm's ability to secure capital, as the current $321.3K cash balance appears insufficient to support long-term clinical milestones."
Verdict Logic
the company's precarious liquidity position, highlighted by a current ratio of 0.26 and a cash balance of only $321.3K, suggests an imminent risk of further shareholder dilution to fund ongoing operations.
SONN Growth Metrics
Sonnet BioTherapeutics Holdings, Inc. (SONN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-31.25%
5 Years-
3 Years41.91%
TTM1689.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-69.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.07%
Return on Capital
10 Years-1139.46%
5 Years-266.62%
3 Years-306.21%
Last Year-306.21%
Peers Comparison
Key metrics vs top competitors for Sonnet BioTherapeutics Holdings, Inc. (SONN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.26 | $8.6M | -0.32 | 5268.84% | -1611.27% | -312.81% | — | |
| $1.83 | $110.39M | -3.27 | — | — | -0% | — | |
| $13.49 | $1.13B | -25.45 | — | — | -38.92% | — | |
| $0.39 | $57.55M | -1.35 | 31.28% | -998.18% | -84.55% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $21.31 | $1.88B | -6.48 | 627.84% | -112.01% | -256.66% | — |
Compare SONN vs Peers
Sonnet BioTherapeutics Holdings, Inc. (SONN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SONN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SONN Frequently Asked Questions
Sonnet BioTherapeutics Holdings, Inc. (SONN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sonnet BioTherapeutics Holdings, Inc.'s revenue?
Sonnet BioTherapeutics Holdings, Inc. (SONN) reported $1.0M in revenue for fiscal year 2025. This represents a 327% increase from $0.2M in 2008.
How fast is Sonnet BioTherapeutics Holdings, Inc. growing?
Sonnet BioTherapeutics Holdings, Inc. (SONN) grew revenue by 5268.8% over the past year. This is strong growth.
Is SONN profitable?
Sonnet BioTherapeutics Holdings, Inc. (SONN) reported a net loss of $13.6M for fiscal year 2025.
Dividend & Returns
What is SONN's return on equity?
Sonnet BioTherapeutics Holdings, Inc. (SONN) has a return on equity (ROE) of -312.8%. Negative ROE indicates the company is unprofitable.
What is Sonnet BioTherapeutics Holdings, Inc.'s free cash flow?
Sonnet BioTherapeutics Holdings, Inc. (SONN) had negative free cash flow of $10.3M in fiscal year 2025, likely due to heavy capital investments.